As per Future Market Insights’ latest industry analysis, the valuation for the global Clinical Next-Generation Sequencing (NGS) Data Analysis Market was around US$ 2.3 Billion in 2022, and the market is projected to exhibit growth at a CAGR of 17.4% over the forecast period, with an estimated valuation of around US$ 13.1 Billion by 2033.
Increasing prevalence of cancer, rise in geriatric population and lifestyle diseases globally, technological advancements in the field of genomic-based bioinformatics tools, and increasing government funding for life science projects, are some of the significant factors accelerating the market growth.
The demand for precise and quick sequencing interpretation tools and algorithms that may accelerate data processing is growing as clinical next-generation sequencing (NGS) technology progresses and their usage in clinical diagnosis, genomic research, and personalized treatments for a variety of disorders increases.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16757
It is anticipated that sequencing programs would expand in scope because of rising genetic data production and declining sequencing costs. As a result, there is a higher need for complex bioinformatics pipelines that include state-of-the-art, efficient solutions.
Key Takeaways from Market Study
- NGS data analysis & sequencing services is the leading segment as solution and services, and is anticipated to hold a CAGR of 2% between 2023 & 2033, owing to affordability of NGS data analysis & sequencing services.
- Sequencing by synthesis (SBS) segment by technology holds a market value share of around 7% in 2022, because of its capabilities, which include long-insert paired-end reads for efficient sequence assembly, de novo sequencing, and other applications.
- Medical research dominates in term of application of clinical next-generation sequencing (NGS) data analysis with a projected market value share of around 6% in 2022, owing to increasing sequencing based approaches.
- By end user, academic & research institutes held a share of around 7% in 2022, due to increasing adoption of NGS platforms.
- North America held a value share of around 6% in 2022, owing to the advancements made in personalized medicines, NGS, and companion diagnostics in the region.
Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-16757
“The development of next-generation sequencing (NGS) technologies and their increased use in genomic research, clinical diagnosis and personalized treatment for a numerous diseases are driving up the demand for exact and rapid sequencing interpretation tools and algorithms speeding up data analysis, which result in increased market demand,” says an analyst of Future Market Insights.
Market Competition:
The COVID-19 pandemic had a favorable effect on the clinical next-generation sequencing (NGS) data analysis industry, due to the increased implementation of next-generation sequencing (NGS) technology. NGS technology was also used to identify new coronavirus strains and other diseases.
The overall demand for the healthcare sector has increased because of the increased demand. In light of the increased demand for COVID-19-related research, the clinical next-generation sequencing (NGS) data analysis market experienced a jump in demand during the height of the pandemic.
- In September 2022, QIAGEN and Neuron23 collaborated to develop next-generation sequencing companion diagnostics for a novel Parkinson’s disease drug.
- In March 2022, Thermo Fisher Scientific launched the Ion Torrent Genexus Dx Integrated Sequencer, an automated next-generation sequencing (NGS) platform.
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the clinical next-generation sequencing (NGS) data analysis market in its latest study, presenting a historical demand assessment of 2014–2022 and projections for 2023–2033. The global clinical next-generation sequencing (NGS) data analysis market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The research study is based on the solution and services (NGS data analysis tools {sequence alignment tools, alignment visualization tools, gene prediction tools, variant analysis tools, and others}, platforms {next-generation sequencing (NGS) platforms, clinical informatics platforms, and others}, NGS data analysis & sequencing services {whole-genome sequencing (WGS), whole exome sequencing (WES), comprehensive genomic profiling (CGP), custom panels, RNA sequencing, and other sequencing services}, and NGS storage, management & cloud computing platform), technology (sequencing by synthesis (SBS), nanopore sequencing, single-molecule real-time (SMRT) sequencing, and others), application (diagnostics, drug discovery & designing, medical research, and others), end user (hospitals & clinics, academic institutes & research centers, biotechnology companies, life science technology vendors, and others), across seven key regions of the world.
For more Report Customization, connect with us at@ https://www.futuremarketinsights.com/customization-available/rep-gb-16757
Key Companies Profiled:
- Agilent Technologies, Inc.
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific
- BGI Group
- Qiagen
- Roche Diagnostics
- DNAStar, Inc.
- Bio-Rad Laboratories, Inc.
- Congenica Ltd.
- Theragen Etex Inc.
- PerkinElmer, Inc.
- Partek Inc.
- Oxford Nanopore Technologies PLC.
- Pacific Biosciences of California, Inc.
- Golden Helix, Inc.
- BioDatomics
- PierianDx
Key Market Segments Covered in the Clinical Next-Generation Sequencing (NGS) Data Analysis Industry Research
Solution and Services:
- NGS Data Analysis Tools
- Sequence Alignment Tools
- Alignment Visualization Tools
- Gene Prediction Tools
- Variant Analysis Tools
- Others
- Platforms
- Next-Generation Sequencing (NGS) Platforms
- Clinical Informatics Platforms
- Others
- NGS Data Analysis & Sequencing Services
- Whole-Genome Sequencing (WGS)
- Whole Exome Sequencing (WES)
- Comprehensive genomic profiling (CGP)
- Custom Panels
- RNA Sequencing
- Other Sequencing Services
- NGS Storage, Management & Cloud Computing Platform
Use promo code >> FMITODAY to get flat 20% discount
Technology:
- Sequencing by Synthesis (SBS)
- Nanopore Sequencing
- Single-Molecule Real-Time (SMRT) Sequencing
- Others
Application:
- Diagnostics
- Drug Discovery & Designing
- Medical Research
- Others
End User:
- Hospitals & Clinics
- Academic Institutes & Research Centers
- Biotechnology Companies
- Life Science Technology Vendors
- Others
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
